Targeting sarcomas: Novel biological agents and future perspectives

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 937-949

  Mahalingam, Devalingam ^a   Mita, Alain ^a   Sankhala, Kamalesh ^a   Swords, Ronan ^a   Kelly, Kevin ^a   Giles, Francis ^a   Mita, Monica M ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

AKT; Apoptosis; IGF 1R; mTOR; Ras; Sarcoma; VEGF and targeted therapy

Indexed keywords

BEVACIZUMAB; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE; PUMA PROTEIN; REOLYSIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ALOPECIA; ANEMIA; ANGIOGENESIS; APOPTOSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOGENESIS; CARDIOMYOPATHY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG RESEARCH; DRUG TARGETING; DRY SKIN; EDEMA; EPIPHORA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE DELETION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HEADACHE; HEART DISEASE; HEMOPTYSIS; HUMAN; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INTESTINE PERFORATION; LUNG EMBOLISM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; OSTEOSARCOMA; PNEUMOTHORAX; PROTEIN EXPRESSION; RASH; REOVIRUS; REVIEW; SARCOMA; SKIN DISCOLORATION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPREGULATION; WOUND DEHISCENCE;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; BONE NEOPLASMS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 70450196419     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577990     Document Type: Review

References (131)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, CA: A Cancer Clin 2008; 58(2): 71-96.
2. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25(19): 2755-2763
3. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007; 26(1): 1-18.
4. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12(8): 1007-1018
5. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin pract 2008; 5(2): 102-111
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408(6810): 307-310
7. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med 1997; 121(4): 395-399
8. Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996; 56(18): 4134-4136
9. Chandar N, Billig B, McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br Cancer 1992; 65(2): 208-214
10. Sztan M, Papai Z, Szendroi M, Looij M, Olah E. Allelic Losses from Chromosome 17 in human osteosarcomas. Pathol Oncol Res 1997; 3(2): 115-120
11. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145(1): 1-30.
12. Nishio J, Gentry JD, Neff JR, Nelson M, Daniels W, Perry D, et al. Monoallelic deletion of the p53 gene through chromosomal translocation in a small cell osteosarcoma. Virchows Arch 2006; 448(6): 852-856
13. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53(1): 16-18
14. Slominski A, Wortsman J, Carlson A, Mihm M, Nickoloff B, McClatchey K. Molecular pathology of soft tissue and bone tumors. A review. Arch Pathol Lab Med 1999; 123(12): 1246-1259
15. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev 2002; 2(7): 489-501.
16. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13(6): 748-753
17. Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008; 113(6): 1453-1461
18. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 2006; 19(1): 106-114
19. Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tanaka K, et al. PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma. Oncol Reports 2004; 11(5): 1011-1015
20. Amant F, de la Rey M, Dorfling CM, van der Walt L, Dreyer G, Dreyer L, et al. PTEN mutations in uterine sarcomas. Gynecologiconcol 2002; 85(1): 165-169
21. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev 2001; 1(3): 222-231
22. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55(24): 6006-6011
23. Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. Nat Cancer Inst 1991; 83(3): 194-200.
24. Barrios C, Castresana JS, Ruiz J, Kreicbergs A. Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 1994; 51(1): 13-17
25. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 1993; 2(3): 163-167
26. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Develop 2002 ; 16(19): 2530-2543
27. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005' 6(8): 635-645
28. Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T. Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol (Noisy-le-Grand, France) 1993; 39(2): 235-242
29. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996; 149(4): 1209-1219
30. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995; 10(4): 739-749
31. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl Transferase Inhib Lipid Res 2006; 47(1): 15-31.
32. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26(22): 3291-3310
33. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Biol 2000; 10(4): 147-154
34. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7(2): 435-442
35. Akatsu T, Tsugita M, Ro S, Kameyama K, Kitajima M. Primary malignant fibrous histiocytoma of the pancreas: a case with K-ras mutation and a review of the literature. Dig Dis Sci 2005; 50(12): 2214-2217
36. Hill MA, Gong C, Casey TJ, Menon AG, Mera R, Gillespie AT, et al. Detection of K-ras mutations in resected primary leiomyosarcoma. Cancer Epidemiol Biomarkers Prev 1997; 6(12): 1095-1100
37. Yoo J, Robinson RA, Lee JY. H-ras and K-ras gene mutations in primary human soft tissue sarcoma: concomitant mutations of the ras genes. Mod Pathol 1999; 12(8): 775-780
38. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Ann Rev Cell Develop Biol 1997; 13: 513-609.
39. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003; 134(2): 221-226 (Pubitemid 37070342)
40. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7(5): 421-427
41. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007; 67(6): 2800-2808
42. Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene 2001; 20(13): 1601-1606
43. Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 2005; 65(16): 7214-7222
44. Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol/Hematol 2007; 63(2): 111-124
45. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007; 110(10): 2293-2303 (Pubitemid 350100752)
46. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005; 41(9): 1349-1361 (Pubitemid 40813013)
47. Ahlen J, Wejde J, Brosjo O, von Rosen A, Weng WH, Girnita L, et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005; 11(1): 206-216 (Pubitemid 40075797)
48. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22(18): 3813-3825
49. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279(5350): 577-580 (Pubitemid 28067289)
50. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299(5607): 708-710 (Pubitemid 36159485)
51. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 2005; 103(9): 1881-1890 (Pubitemid 40563261)
52. Tawbi H, Thomas D, Lucas DR, Biermann JS, Schuetze SM, Hart AL, et al. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 2008; 13(4): 459-466 (Pubitemid 351679927)
53. Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006; 19(4): 541-547
54. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002; 8(3): 788-793 (Pubitemid 34742109)
55. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Therap 2007; 6(1): 1-12. (Pubitemid 46206663)
56. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opincol 2008; 20(4): 419-427
57. Carpenter G, Cohen S. Epidermal growth factor. Biol Chem 1990; 265(14): 7709-7712
58. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88(4): 435-437
59. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997; 277(5325): 567-570
60. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411(6835): 355-365
61. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428(6980): 332-337 (Pubitemid 38418805)
62. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E - from translation to transformation. Oncogene 2004; 23(18): 3172-3179
63. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123(4): 569-580
64. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431(7005): 200-205 (Pubitemid 39243474)
65. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82(3): 673-700.
66. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14(3): 285-294 (Pubitemid 47057799)
67. Miller KD, Sweeney CJ, Sledge GW, Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19(4): 1195-1206
68. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001; 276(52): 49289-49298 (Pubitemid 37370640)
69. Takahashi R, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003; 64(3): 266-274 (Pubitemid 36438812)
70. Hong T, Shimada Y, Uchida S, Itami A, Li Z, Ding Y, et al. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001; 8(2): 141-148
71. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 2000; 6(2): 572-577 (Pubitemid 30111481)
72. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999; 35(7): 1089-1093
73. Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, et al. Randomized, Phase II study of the Thrombospondin-1-Mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008; 26 (34): 5583-5588
74. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285(5425): 245-248 (Pubitemid 29329995)
75. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. Biol Chem 2006; 281(6): 3604-3613 (Pubitemid 43845978)
76. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8(4): 349-357 (Pubitemid 34407029)
77. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007; 14(7): 616-626 (Pubitemid 46912035)
78. Ek ET, Dass CR, Choong PF. Pigment epithelium-derived factor: a multimodal tumor inhibitor. Mol Cancer Therap 2006; 5(7): 1641-1646 (Pubitemid 44323231)
79. Folkman J, Shing Y. Angiogenesis. Biol Chem 1992; 267(16): 10931-10934
80. Samali A, Zhivotovsky B, Jones D, Nagata S, Orrenius S. Apoptosis: cell death defined by caspase activation. Cell Death Differ 1999; 6(6): 495-496 (Pubitemid 29292104)
81. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004; 100(9): 1936-1942 (Pubitemid 38529571)
82. Sabah M, Cummins R, Leader M, Kay E. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. Appl Immunohistochem Mol Morphol 2007; 15(1): 64-69
83. Nedelcu T, Kubista B, Koller A, Sulzbacher I, Mosberger I, Arrich F, et al. Livin and Bcl-2 expression in high-grade osteosarcoma. Cancer Res Clin Oncol 2008; 134(2): 237-244 (Pubitemid 350234069)
84. Rodriguez E, Sreekantaiah C, Gerald W, Reuter VE, Motzer RJ, Chaganti RS. A recurring translocation, t(11;22)(p13;q11.2), characterizes intra-abdominal desmoplastic small round-cell tumors. Cancer Genet Cytogenet 1993; 69(1): 17-21. (Pubitemid 23280173)
85. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62(1): 135-140
86. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006; 48(1): 13-21.
87. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004; 10(4): 1344-1353 (Pubitemid 38365227)
88. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004; 22(20): 4040-4050
89. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103(4): 830-838 (Pubitemid 40216413)
90. Aigner T, Dertinger S, Vornehm SI, Dudhia J, von der Mark K, Kirchner T. Phenotypic diversity of neoplastic chondrocytes and extracellular matrix gene expression in cartilaginous neoplasms. Am Pathol 1997; 150(6): 2133-2141 (Pubitemid 27233084)
91. Boeuf S, Kunz P, Hennig T, Lehner B, Hogendoorn P, Bovee J, et al. A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma. Pathology 2008; 216(2): 158-166
92. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26(4): 620-625
93. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23): 4342-4349
94. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26 (33): 5360-5367
95. Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008; 15(1): 47-54.
96. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368(9544): 1329-1338
97. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006; 368(9544): 1303-1304
98. Maki RG, Keoghan ML, Undevia SD, Livingston M, Cooney MM, Elias A, Saulle MF et al. Sorafenib Sarcoma Study Group. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. J Clin Oncol 26: 2008 (May 20 suppl; abstr 10531).
99. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124(3): 471-484
100. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369(6483): 756-758 (Pubitemid 24225367)
101. Chawla SP, Tolcher AW, Staddon AP, Menendez LR, Eilber FC, Eckardt JJ, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas. J Clin Oncol, ASCO Annual meeting Proceedings. 2006; 24(18S).
102. Sankhala K, Chawala SP, Iagaru A, Dellamaggiora R, Chua V, Daly S, et al. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma Fluoro-2-Deoxy-D-Glucose (FDG) positron emission tomography (PET) scan. Proc Annu Meet Am Soc Clin Oncol 2005; 23.
103. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26(13):1932-1940 (Pubitemid 46474636)
104. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral Oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 1998; 17(12): 3351-3362 (Pubitemid 28279509)
105. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282 (5392): 1332-1334
106. Eckschlager T, Figova K. Reolysin(R) - Oncolytic virus. Drugs Future 2008; 33 (6): 489-495
107. Mita M. A Phase II Study of intravenous REOLYSIN (Wild type REOVIRUS) in the treatment of patients with bone AND soft tissue sarcomas metastatic to the lung. Abstract 350670. CTOS 14th Annual Meeting 2008.
108. Mahalingam D, Giles F. Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Therap Targets 2008; 12 (11): 1389-1401
109. Buchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia 2007; 9 (2):119-127 (Pubitemid 46318370)
110. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. New Engl J Med. 2004; 350 (23): 2335-2342
111. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-Carboplatin alone or with Bevacizumab for Non-Small-Cell Lung cancer. New Engl J Med 2006; 355 (24): 2542-2550 (Pubitemid 44917502)
112. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic breast cancer. N Engl J Med 2007; 357 (26): 2666-2676
113. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23 (28): 7135-7142 (Pubitemid 46260301)
114. Verschraegen CF, Quinn R, Rabinowitz I, Arias-Pulido H, Muller C, New Mexico Cancer Care Alliance. Phase I/II study of docetaxel (D), gemcitabine (G), and bevacizumab (B) in patients (pts) with advanced or recurrent soft tissue sarcoma (STS). J Clin Oncol 26: 2008 (May 20 suppl; abstr 10534).
115. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Intl J Cancer 2002; 98 (5): 682-689 (Pubitemid 34225618)
116. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005; 23 (25): 6172-6180 (Pubitemid 46300236)
117. Ray-Coquard I, Le Cesne A, Whelan JS, Schoffski P, Bui BN, Verweij J, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008; 4: 467-473 (Pubitemid 351679928)
118. Gatzemeier U. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. Oncology (Williston Park, NY. 2003; 17(11 Suppl 12): 7-10.
119. Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54(3): 133-137 (Pubitemid 32539602)
120. Rodon J, DeSantos V, Ferry RJ, Jr., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Therap 2008 Sep;7 (9): 2575-2588
121. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res, 2005; 65 (9): 3868-3876 (Pubitemid 40616368)
122. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood Cancer 2008; 50 (6): 1190-1197 (Pubitemid 351555543)
123. Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA,Yap TA, et al . Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol25, No 18S (June 20 Supplement), 2007: 3586.
124. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST). J Clin Oncol 26: 2008 (May 20 suppl; abstr 3582).
125. Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I Vol25, No 18S (June 20 Supplement), 2007: 3002.
126. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I Vol25, No 18S (June 20 Supplement), 2007: 3590.
127. Magenau JM, Schuetze SM. New targets for therapy of sarcoma. Curr Opin Oncol 2008; 20 (4): 400-406
128. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002; 347 (7): 472-480
129. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440):1127-1134 (Pubitemid 39296599)
130. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26 (33): 5360-5367
131. Leong S, Gore L, Benjamin R, Warren TL, Eckhardt SG, Camidge DR, et al. A phase I study of R1507, a human monoclonal antibody lGF1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Mol Cancer Ther 2007; 6 (12): 3360 s-s.